Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 2, 2016

AbbVie and EA Pharma to co-promote Humira for gastrointestinal diseases

AbbVie, along with EA Pharma, a subsidiary of Japanese pharmaceutical company Eisai, will begin the co-promotion of fully human anti-TNF-alpha monoclonal antibody Humira for indications in the field of gastrointestinal diseases.

AbbVie, along with EA Pharma, a subsidiary of Japanese pharmaceutical company Eisai, will begin the co-promotion of fully human anti-TNF-alpha monoclonal antibody Humira for indications in the field of gastrointestinal diseases.

Humira is a fully human, anti-tumour necrosis factors (TNF)-alpha monoclonal antibody.

EA Pharma was established in April this year through the integration of Eisai’s gastrointestinal disease business, and along with Ajinamoto Pharmaceuticals, is a gastrointestinal specialty pharmaceutical firm with a full value chain including research and development, production and logistics, and sales and marketing.

Eisai has assigned the responsibility to EA Pharma to undertake co-promotion on gastrointestinal disease indications for Humira with Abbvie.

"Eisai has assigned the responsibility to EA Pharma to undertake co-promotion on gastrointestinal disease indications for Humira with Abbvie."

There will be no change to the distribution and sales framework for Humira, as AbbVie will continue to be the marketing and manufacturing authorisation holder for Humira, while Eisai is responsible for its distribution.

AbbVie and Eisai will continue the co-promotion for Humira of indications outside of the gastrointestinal disease field such as the treatment of rheumatoid arthritis, including prevention of structural joint damage.

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Humira will also be used for diseases that do not sufficiently respond to existing treatments.

The diseases include psoriasis vulgaris, arthropathic psoriasis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.

The three companies will continue to promote and provide data on the proper use of Humira, while making further contributions to improve the patients’ quality of life.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU